Intellia Therapeutics Inc’s recent filing unveils that its EVP, Chief Scientific Officer Schultes Birgit C unloaded Company’s shares for reported $539.0 on Oct 01 ’25. In the deal valued at $17.38 per share,31 shares were sold. As a result of this transaction, Schultes Birgit C now holds 105,184 shares worth roughly $0.89 million.
Then, Dube Michael P sold 1,871 shares, generating $32,518 in total proceeds. Upon selling the shares at $17.38, the VP, Chief Accounting Officer now owns 55,266 shares.
Before that, CHASE WILLIAM J bought 100,000 shares. Intellia Therapeutics Inc shares valued at $1,003,000 were divested by the Director at a price of $10.03 per share. As a result of the transaction, CHASE WILLIAM J now holds 134,693 shares, worth roughly $1.14 million.
Wolfe Research downgraded its Intellia Therapeutics Inc [NTLA] rating to a Peer perform from a an Outperform in a research note published recently. A number of analysts have revised their coverage, including Evercore ISI’s analysts, who decreased its forecast for the stock in mid November from “an Outperform” to “an In-line”. JP Morgan also remained covering NTLA and has decreased its forecast on November 07, 2025 with a “an Underweight” recommendation from previously “Neutral” rating. RBC Capital Mkts revised its rating on October 28, 2025. It rated NTLA as “a Sector perform” which previously was an “an Outperform”.
Price Performance Review of NTLA
On Monday, Intellia Therapeutics Inc [NASDAQ:NTLA] saw its stock fall -2.53% to $8.48. Over the last five days, the stock has lost -12.85%. Intellia Therapeutics Inc shares have fallen nearly -47.36% since the year began. Nevertheless, the stocks have fallen -27.27% over the past one year. While a 52-week high of $28.25 was reached on 10/20/25, a 52-week low of $5.90 was recorded on 04/07/25.
Levels Of Support And Resistance For NTLA Stock
The 24-hour chart illustrates a support level at 8.20, which if violated will result in even more drops to 7.93. On the upside, there is a resistance level at 8.78. A further resistance level may holdings at 9.08.
How much short interest is there in Intellia Therapeutics Inc?
A steep rise in short interest was recorded in Intellia Therapeutics Inc stocks on 2025-10-31, growing by 9.34 million shares to a total of 39.08 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-30 was 29.74 million shares. There was a rise of 23.89%, which implies that there is a positive sentiment for the stock.
